Supplementary Figure 1 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

Pedram Kharaziha,Hendrik De Raeve, Charlotte Fristedt, Qiao Li,Astrid Gruber,Per Johnsson,Georgia Kokaraki,Maria Panzar, Edward Laane,Anders Österborg,Boris Zhivotovsky,Helena Jernberg-Wiklund,Dan Grandér, Fredrik Celsing,Magnus Björkholm,Karin Vanderkerken,Theocharis Panaretakis

crossref（2023）

引用 0|浏览4

暂无评分

摘要

PDF file - 26K, The indicated myeloma cell lines were treated with 10 muM Sor for 24h and cell cycle distribution was analysed by NucleoCounter NC-3000 (Chemometec).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure 1 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma &lt;i&gt;In Vitro&lt;/i&gt;, &lt;i&gt;Ex Vivo&lt;/i&gt;, and &lt;i&gt;In Vivo&lt;/i&gt; in the 5T33MM Mouse Model

Supplementary Figure 1 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma <i>In Vitro</i>, <i>Ex Vivo</i>, and <i>In Vivo</i> in the 5T33MM Mouse Model